Logo image of EPRX.CA

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Fundamental Analysis

TSX:EPRX - Toronto Stock Exchange - CA29842P1053 - Common Stock - Currency: CAD

5.28  +0.22 (+4.35%)

Fundamental Rating

3

Overall EPRX gets a fundamental rating of 3 out of 10. We evaluated EPRX against 25 industry peers in the Biotechnology industry. While EPRX has a great health rating, there are worries on its profitability. EPRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EPRX has reported negative net income.
In the past year EPRX has reported a negative cash flow from operations.
EPRX had negative earnings in each of the past 5 years.
In the past 5 years EPRX always reported negative operating cash flow.
EPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFEPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of EPRX (-445.87%) is worse than 75.00% of its industry peers.
EPRX has a better Return On Equity (-485.43%) than 70.00% of its industry peers.
Industry RankSector Rank
ROA -445.87%
ROE -485.43%
ROIC N/A
ROA(3y)-100.92%
ROA(5y)-159.37%
ROE(3y)-522.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX.CA Yearly ROA, ROE, ROICEPRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 1K -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EPRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX.CA Yearly Profit, Operating, Gross MarginsEPRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, EPRX has more shares outstanding
EPRX has more shares outstanding than it did 5 years ago.
EPRX has a worse debt/assets ratio than last year.
EPRX.CA Yearly Shares OutstandingEPRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
EPRX.CA Yearly Total Debt VS Total AssetsEPRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

An Altman-Z score of 63.84 indicates that EPRX is not in any danger for bankruptcy at the moment.
The Altman-Z score of EPRX (63.84) is better than 100.00% of its industry peers.
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.84
ROIC/WACCN/A
WACCN/A
EPRX.CA Yearly LT Debt VS Equity VS FCFEPRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M -20M

2.3 Liquidity

EPRX has a Current Ratio of 4.17. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
EPRX has a better Current ratio (4.17) than 80.00% of its industry peers.
A Quick Ratio of 4.17 indicates that EPRX has no problem at all paying its short term obligations.
EPRX's Quick ratio of 4.17 is fine compared to the rest of the industry. EPRX outperforms 80.00% of its industry peers.
Industry RankSector Rank
Current Ratio 4.17
Quick Ratio 4.17
EPRX.CA Yearly Current Assets VS Current LiabilitesEPRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

EPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.76%, which is quite good.
EPS 1Y (TTM)9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.24% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.17%
EPS Next 2Y19.67%
EPS Next 3Y25.99%
EPS Next 5Y13.24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX.CA Yearly Revenue VS EstimatesEPRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
EPRX.CA Yearly EPS VS EstimatesEPRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EPRX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EPRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX.CA Price Earnings VS Forward Price EarningsEPRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX.CA Per share dataEPRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

EPRX's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.67%
EPS Next 3Y25.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUPRAXIA PHARMACEUTICALS INC

TSX:EPRX (2/21/2025, 7:00:00 PM)

5.28

+0.22 (+4.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners13.09%
Inst Owner ChangeN/A
Ins Owners22.83%
Ins Owner ChangeN/A
Market Cap188.23M
Analysts85
Price Target12.62 (139.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.52%
Min EPS beat(2)2.06%
Max EPS beat(2)12.99%
EPS beat(4)3
Avg EPS beat(4)-5.49%
Min EPS beat(4)-55.23%
Max EPS beat(4)18.21%
EPS beat(8)7
Avg EPS beat(8)5.91%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)49.49%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 13.93
P/tB 13.93
EV/EBITDA N/A
EPS(TTM)-1.6
EYN/A
EPS(NY)-0.98
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.99
OCFYN/A
SpS0
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -445.87%
ROE -485.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.92%
ROA(5y)-159.37%
ROE(3y)-522.33%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 280%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.17
Quick Ratio 4.17
Altman-Z 63.84
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)206.36%
Cap/Depr(5y)124.82%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%7.2%
EPS Next Y50.17%
EPS Next 2Y19.67%
EPS Next 3Y25.99%
EPS Next 5Y13.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-53.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.62%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-44.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.16%
OCF growth 3YN/A
OCF growth 5YN/A